stockportfolio.pro
Stocks / CRNX vs NAMS
CRNX vs NAMS
Crinetics Pharmaceuticals, Inc. and NewAmsterdam Pharma Company N.V. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Crinetics Pharmaceuticals, Inc. (CRNX) | NewAmsterdam Pharma Company N.V. (NAMS) | |
|---|---|---|
| Market cap | $3.5B | $3.5B |
| Revenue (latest FY) | $7.70M | $22.50M |
| Net income (latest FY) | $-465.32M | $-203.82M |
| Revenue growth (5y CAGR) | 155.3% | — |
| Net margin | -6046.2% | -905.7% |
| Return on equity | -46.9% | -29.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open CRNX — free Open NAMS — freeFrequently asked questions
Which is bigger, CRNX or NAMS?
NewAmsterdam Pharma Company N.V. is larger by market capitalization — $3.5B versus $3.5B.
Which grows faster, CRNX or NAMS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.